Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -798.00K | -895.80K | -1.47M | -1.51M | -1.51M |
| Total Depreciation and Amortization | 22.80K | 33.70K | 33.20K | 32.60K | 32.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.60K | 321.40K | 1.19M | 1.45M | 1.45M |
| Change in Net Operating Assets | -387.00K | -142.10K | 10.00K | 639.50K | 639.50K |
| Cash from Operations | -1.21M | -682.90K | -235.20K | 605.50K | 842.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.81M | -3.88M | -323.10K | -205.40K | -205.40K |
| Cash from Investing | -3.81M | -3.88M | -323.10K | -205.40K | -336.70K |
| Total Debt Issued | -- | -49.50K | 722.00K | 722.00K | 722.00K |
| Total Debt Repaid | -60.10K | -82.90K | -76.10K | -67.40K | -67.40K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -551.70K | -1.11M | -1.61M | -1.61M |
| Cash from Financing | -43.60K | -489.40K | -325.80K | -684.20K | -1.10M |
| Foreign Exchange rate Adjustments | -900.00 | -2.00K | 27.90K | 41.60K | 41.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.07M | -5.06M | -856.20K | -242.40K | -534.30K |